Saltar al contenido principal
xMedica

NCT06535854ClinicalTrials.gov

Prevail Global Study

A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).

En reclutamientoAdmite participantes ahora, según el registro.
Contactar con este estudio

En resumen

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

De intervención1205 participantes buscados79 centros9 países

Categorías

Registrado en 1 registro

Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.

La información del ensayo se muestra tal como la publicó el registro, en su idioma original.

¿Le interesa este estudio?

Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 51 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,205 participants (target), run at 79 sites, across 9 countries.

How this score is built
  • Enrolment31/40

    1,205 participants (target)

  • Site count20/25

    51 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 72 months

  • Sponsor scale3/10

    Medtronic Vascular has led 11 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Resumen

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

The Prevail Global study is a prospective, premarket, interventional, multi-center, global, dual cohort clinical study enrolling subjects undergoing percutaneous coronary intervention for in-stent restenosis (ISR Cohort) in a randomized controlled study of the Prevail Drug-Coated Balloon, and subjects undergoing percutaneous coronary intervention of the Prevail Drug-Coated Balloon for de novo lesions in small vessel disease (DNSV Cohort) in a single arm prospectively enrolled study. In the ISR Cohort this will be accomplished by randomizing subjects to either a Prevail DCB arm or an Agent DCB arm to compare results of the treatment of ISR with coronary lesions previously treated with DES or BMS in native coronary arteries. In the DNSV Cohort this will be accomplished through collection of data to compare results of the Prevail DCB to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease. Subjects will be enrolled at approximately 85 study sites; the same study sites will be used for enrollment of both cohorts. The enrollment period is anticipated to be approximately 12 months. Subjects will remain in the study with follow-up clinical assessments through 5 years, study exit, or death, whichever comes first.

Afecciones

  • Coronary Artery Disease

Elegibilidad

Elegibilidad
SexoTodos
Edades18 Years – Sin máximo
Voluntarios sanosNo

Elegibilidad tal como figura en el registro

Inclusion Criteria: * ≥ 18 years * Negative pregnancy test * Stable or unstable angina, positive functional test, or stable NSTEMI * Life expectancy \>1 year * Willing and able to cooperate with study procedures and required follow up evaluations Exclusion Criteria: * Known hypersensitivity or contraindication to antiplatelet medications or a sensitivity to contrast media which cannot be adequately pre-medicated * History of an allergic reaction or significant sensitivity to paclitaxel or any other analogue or derivative * Platelet count \< 100,000 cells/mm³ or \> 700,000 cells/mm³, or a white blood cell (WBC) count \< 3,000 cells/mm³ * Renal insufficiency (or failure) * Acute MI * Previous PCI of the target vessel within 6 months prior to the procedure * Planned PCI of any vessel within 72 hours post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure * History of a stroke or transient ischemic attack (TIA) * Active peptic ulcer or upper gastrointestinal (GI) bleeding * History of bleeding diathesis or coagulopathy or will refuse blood transfusions * Documented left ventricular ejection fraction (LVEF) \<30% * Planned surgery that would cause interruption in recommended DAPT duration per current guidelines * Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS or other coronary artery imaging procedures

Elegibilidad en frases sencillas

Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.

Diseño del estudio

Diseño del estudio
Tipo de estudioDe intervención
FaseNo aplicable
AsignaciónAleatorizado
Modelo de intervenciónPARALLEL
Propósito principalTREATMENT
EnmascaramientoSINGLE (1)
Inscripción1205 participantes buscados

Patrocinador y colaboradores

  • Medtronic Vascular Patrocinador

Grupos e intervenciones

  • ISR Cohort Prevail DCBEXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.

  • DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.

Intervenciones

  • Dispositivo Agent DCB

    The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).

  • Dispositivo Prevail DCB

    The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.

Variables de resultado

  1. Variable de resultado principal

    ISR Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority

    Plazo 1 year post-procedure

  2. Variable de resultado principal

    DNSV Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control

    Plazo 1 year post-procedure

  3. Variable de resultado secundaria

    Acute success

    Acute success (device, lesion, and procedure) through hospital discharge only

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  4. Variable de resultado secundaria

    All deaths

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  5. Variable de resultado secundaria

    Cardiac death

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  6. Variable de resultado secundaria

    All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  7. Variable de resultado secundaria

    Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  8. Variable de resultado secundaria

    Clinically-driven target vessel revascularization (cd-TVR)

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  9. Variable de resultado secundaria

    Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  10. Variable de resultado secundaria

    Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  11. Variable de resultado secundaria

    Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  12. Variable de resultado secundaria

    Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition

    Plazo hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

Fechas

Fechas
Fecha de inicio24 de febrero de 2025 (real)
Finalización principal1 de febrero de 2027 (estimada)
Finalización1 de febrero de 2031 (estimada)
Primera publicación2 de agosto de 2024 (real)
Última actualización21 de octubre de 2026
Resultados publicadosNo indicado en el registro
Estado verificado por última vezoctubre de 2026

Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.

Ubicaciones

78 centros están en reclutamiento

Canada

Canada
CentroCiudadEstado o regiónEstado
Montreal Heart InstituteMontrealEn reclutamiento
Hôpital du Sacre Coeur de MontrealMontrealEn reclutamiento
University of Ottawa Heart InstituteOttawaEn reclutamiento
Toronto General HospitalTorontoEn reclutamiento
Vancouver General HospitalVancouverEn reclutamiento

Germany

Germany
CentroCiudadEstado o regiónEstado
Herzzentrum Dresden GmbH UniversitätsklinikDresdenEn reclutamiento
Universitat des SaarlandesHomburgEn reclutamiento
MediClin Herzzentrum Lahr / BadenLahrEn reclutamiento

Hong Kong

Hong Kong
CentroCiudadEstado o regiónEstado
Queen Mary HospitalHong KongEn reclutamiento

Ireland

Ireland
CentroCiudadEstado o regiónEstado
Mater Private NetworkDublinEn reclutamiento
Galway University Hospitals - University Hospital Galway (UHG)GalwayEn reclutamiento

Japan

Japan
CentroCiudadEstado o regiónEstado
Teikyo University HospitalItabashi-kuTokyoEn reclutamiento
Shonan Kamakura General HospitalKamakuraKanagawaEn reclutamiento
Kokura Memorial HospitalKitakyushuFukuokaEn reclutamiento
Sendai Kousei HospitalSendaiMiyagiEn reclutamiento
Saiseikai Yokohamashi Tobu HospitalYokohamaKanagawaEn reclutamiento

Singapore

Singapore
CentroCiudadEstado o regiónEstado
Sengkang General HospitalSingaporeEn reclutamiento
Tan Tock Seng HospitalSingaporeEn reclutamiento

South Korea

South Korea
CentroCiudadEstado o regiónEstado
Keimyung University Dongsan HospitalDaeguEn reclutamiento
Korea University Anam HospitalSeoulEn reclutamiento
Seoul Saint Marys HospitalSeoulEn reclutamiento
Seoul National University HospitalSeoulEn reclutamiento
Asan Medical CenterSeoulEn reclutamiento

United Kingdom

United Kingdom
CentroCiudadEstado o regiónEstado
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman HospitalNewcastle upon TyneEn reclutamiento

United States

United States
CentroCiudadEstado o regiónEstado
Lehigh Valley Hospital - Cedar CrestAllentownPennsylvaniaEn reclutamiento
AnMed Health Medical CenterAndersonSouth CarolinaEn reclutamiento
University of Michigan Health System - University HospitalAnn ArborMichiganEn reclutamiento
Emory University Hospital MidtownAtlantaGeorgiaEn reclutamiento
Piedmont Atlanta HospitalAtlantaGeorgiaEn reclutamiento
The University of Alabama at BirminghamBirminghamAlabamaEn reclutamiento
Cardiology P.C.BirminghamAlabamaEn reclutamiento
Kaleida HealthBuffaloNew YorkEn reclutamiento
Virtua Our Lady of Lourdes HospitalCamdenNew JerseyEn reclutamiento
Medical University of South Carolina (MUSC)CharlestonSouth CarolinaEn reclutamiento
Advocate Illinois Masonic Medical CenterChicagoIllinoisEn reclutamiento
The Lindner Research CenterCincinnatiOhioEn reclutamiento
BayCare Health SystemClearwaterFloridaEn reclutamiento
University Hospitals Cleveland Medical CenterClevelandOhioEn reclutamiento
OhioHealth Riverside Methodist HospitalColumbusOhioEn reclutamiento
Baylor Heart & Vascular HospitalDallasTexasEn reclutamiento
Saint Elizabeth HealthcareEdgewoodKentuckyEn reclutamiento
M Health Fairview ClinicEdinaMinnesotaRetirado
Parkview HealthFort WayneIndianaEn reclutamiento
North Florida Regional Medical CenterGainesvilleFloridaEn reclutamiento
Corewell HealthGrand RapidsMichiganEn reclutamiento
The Moses H Cone Memorial HospitalGreensboroNorth CarolinaEn reclutamiento
UPMC Pinnacle Harrisburg CampusHarrisburgPennsylvaniaEn reclutamiento
HCA Houston Medical CenterHoustonTexasEn reclutamiento
Huntsville HospitalHuntsvilleAlabamaEn reclutamiento
Saint Lukes Mid America Heart InstituteKansas CityMissouriEn reclutamiento

En el registro figuran 29 centros más.

Documentos del estudio

No hay documentos enlazados en este registro.

Cambios a lo largo del tiempo

  1. 21 de octubre de 2026

    Centro añadido

    28 sites added (79 total)

    5179